Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06029270

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Led by National Cancer Institute (NCI) · Updated on 2026-05-13

156

Participants Needed

79

Research Sites

250 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. The usual approach of treatment is initial treatment with chemotherapy such as the combination of cisplatin (or carboplatin) and gemcitabine, along with immunotherapy such as nivolumab. After the initial treatment is finished, patients may continue to receive additional immunotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Giving BMS-986016 in addition to the usual immunotherapy after initial treatment may extend the time without the tumor cells growing or spreading longer than the usual approach in patients with recurrent or metastatic nasopharyngeal cancer.

CONDITIONS

Official Title

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of nasopharyngeal carcinoma (NPC) that is recurrent or metastatic, confirmed by pathology
  • Tumor must be Epstein-Barr encoded RNA positive or have a history of detectable plasma Epstein-Barr virus DNA
  • Measurable disease by RECIST 1.1 criteria, including lesions previously irradiated if progression is shown
  • Age 18 years or older
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Negative pregnancy test for persons of childbearing potential within 14 days prior to registration
  • Adequate blood counts: neutrophils >= 1500 cells/mm3, platelets >= 100,000 cells/mm3, hemoglobin >= 8.0 g/dL
  • Liver and kidney function within specified limits including bilirubin, ALT, creatinine levels
  • No prior systemic treatment for palliative intent of recurrent/metastatic NPC
  • No prior treatment with PD-1, PD-L1, LAG-3, CTLA-4 inhibitors except as adjuvant/neoadjuvant for non-recurrent, non-metastatic NPC
  • At least 6 months since last curative-intent treatment and recurrence
  • Clinically stable with resolved toxicities from prior treatments except certain mild conditions
  • No recent palliative radiotherapy or major surgery within 30 days prior to registration
  • No recent unstable angina or myocardial infarction within 6 months
  • Heart function NYHA class II or better
  • No prior myocarditis
  • No active infection requiring IV antimicrobial treatment
  • No history of pneumonitis requiring steroids or current pneumonitis
  • No active or recent multi-drug resistant tuberculosis
  • No prior solid organ or bone marrow transplant
  • No recent systemic immunosuppressive treatment within 14 days
  • No active autoimmune disease requiring systemic treatment within past 2 years except certain permitted conditions
  • No prior live vaccines within 30 days prior to registration
  • No history of severe allergic reactions to study drugs
  • Required plasma Epstein-Barr virus DNA samples collected prior to treatment and randomization
  • Completion of 3 to 6 cycles of induction treatment within 20 weeks without disease progression or unacceptable toxicity
  • Appropriate imaging within 30 days prior to randomization
Not Eligible

You will not qualify if you...

  • Disease amenable to potentially curative surgery or re-irradiation for locoregional recurrence
  • Disease directly invading brain parenchyma with symptoms or significant brain swelling
  • ECOG performance status worse than 2
  • Positive pregnancy test or potential for pregnancy without adequate contraception
  • Inability to meet blood count or organ function criteria
  • Prior systemic treatment of palliative intent for recurrent/metastatic NPC
  • Prior use of immune checkpoint inhibitors except as allowed for non-recurrent NPC
  • Recent major surgery or radiotherapy within specified time frames
  • Unstable cardiovascular conditions or recent serious heart events
  • History of myocarditis
  • Active infections requiring IV antimicrobial treatment
  • History or presence of pneumonitis requiring steroids
  • Active tuberculosis or recent treatment within 2 years
  • Prior organ or bone marrow transplant
  • Use of systemic immunosuppressive medications within 14 days
  • Active autoimmune diseases needing systemic treatment within 2 years except specified exceptions
  • Receipt of live vaccines within 30 days before registration
  • History of severe allergic reaction to study drugs or monoclonal antibodies

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 79 locations

1

Kaiser Permanente Dublin

Dublin, California, United States, 94568

Actively Recruiting

2

Kaiser Permanente-Fremont

Fremont, California, United States, 94538

Actively Recruiting

3

Kaiser Permanente Fresno Orchard Plaza

Fresno, California, United States, 93720

Actively Recruiting

4

Kaiser Permanente-Fresno

Fresno, California, United States, 93720

Actively Recruiting

5

Keck Medicine of USC Koreatown

Los Angeles, California, United States, 90020

Actively Recruiting

6

Los Angeles General Medical Center

Los Angeles, California, United States, 90033

Actively Recruiting

7

USC / Norris Comprehensive Cancer Center

Los Angeles, California, United States, 90033

Actively Recruiting

8

Kaiser Permanente- Modesto MOB II

Modesto, California, United States, 95356

Actively Recruiting

9

Kaiser Permanente-Modesto

Modesto, California, United States, 95356

Actively Recruiting

10

USC Norris Oncology/Hematology-Newport Beach

Newport Beach, California, United States, 92663

Actively Recruiting

11

Kaiser Permanente-Oakland

Oakland, California, United States, 94611

Actively Recruiting

12

Stanford Cancer Institute Palo Alto

Palo Alto, California, United States, 94304

Actively Recruiting

13

Kaiser Permanente-Roseville

Roseville, California, United States, 95661

Actively Recruiting

14

Kaiser Permanente Downtown Commons

Sacramento, California, United States, 95814

Actively Recruiting

15

University of California Davis Comprehensive Cancer Center

Sacramento, California, United States, 95817

Actively Recruiting

16

Kaiser Permanente-South Sacramento

Sacramento, California, United States, 95823

Actively Recruiting

17

Kaiser Permanente-San Francisco

San Francisco, California, United States, 94115

Actively Recruiting

18

Kaiser Permanente-Santa Teresa-San Jose

San Jose, California, United States, 95119

Actively Recruiting

19

Kaiser Permanente San Leandro

San Leandro, California, United States, 94577

Actively Recruiting

20

Kaiser San Rafael-Gallinas

San Rafael, California, United States, 94903

Actively Recruiting

21

Kaiser Permanente Medical Center - Santa Clara

Santa Clara, California, United States, 95051

Actively Recruiting

22

Kaiser Permanente-Santa Rosa

Santa Rosa, California, United States, 95403

Actively Recruiting

23

Kaiser Permanente-South San Francisco

South San Francisco, California, United States, 94080

Actively Recruiting

24

Kaiser Permanente-Vallejo

Vallejo, California, United States, 94589

Actively Recruiting

25

Kaiser Permanente-Walnut Creek

Walnut Creek, California, United States, 94596

Actively Recruiting

26

Emory University Hospital Midtown

Atlanta, Georgia, United States, 30308

Actively Recruiting

27

Kaiser Permanente Moanalua Medical Center

Honolulu, Hawaii, United States, 96819

Actively Recruiting

28

Saint Alphonsus Cancer Care Center-Boise

Boise, Idaho, United States, 83706

Suspended

29

Saint Alphonsus Cancer Care Center-Caldwell

Caldwell, Idaho, United States, 83605

Suspended

30

Kootenai Health - Coeur d'Alene

Coeur d'Alene, Idaho, United States, 83814

Actively Recruiting

31

Saint Alphonsus Cancer Care Center-Nampa

Nampa, Idaho, United States, 83687

Suspended

32

Kootenai Clinic Cancer Services - Post Falls

Post Falls, Idaho, United States, 83854

Actively Recruiting

33

Kootenai Clinic Cancer Services - Sandpoint

Sandpoint, Idaho, United States, 83864

Actively Recruiting

34

Northwestern University

Chicago, Illinois, United States, 60611

Actively Recruiting

35

University of Illinois

Chicago, Illinois, United States, 60612

Actively Recruiting

36

Carle at The Riverfront

Danville, Illinois, United States, 61832

Actively Recruiting

37

Northwestern Medicine Cancer Center Kishwaukee

DeKalb, Illinois, United States, 60115

Actively Recruiting

38

Carle Physician Group-Effingham

Effingham, Illinois, United States, 62401

Actively Recruiting

39

Northwestern Medicine Cancer Center Delnor

Geneva, Illinois, United States, 60134

Actively Recruiting

40

Northwestern Medicine Glenview Outpatient Center

Glenview, Illinois, United States, 60026

Actively Recruiting

41

Northwestern Medicine Grayslake Outpatient Center

Grayslake, Illinois, United States, 60030

Actively Recruiting

42

Northwestern Medicine Lake Forest Hospital

Lake Forest, Illinois, United States, 60045

Actively Recruiting

43

Carle Physician Group-Mattoon/Charleston

Mattoon, Illinois, United States, 61938

Actively Recruiting

44

Northwestern Medicine Orland Park

Orland Park, Illinois, United States, 60462

Actively Recruiting

45

Carle Cancer Center

Urbana, Illinois, United States, 61801

Actively Recruiting

46

Northwestern Medicine Cancer Center Warrenville

Warrenville, Illinois, United States, 60555

Actively Recruiting

47

Heartland Oncology and Hematology LLP

Council Bluffs, Iowa, United States, 51503

Suspended

48

Methodist Jennie Edmundson Hospital

Council Bluffs, Iowa, United States, 51503

Actively Recruiting

49

Nebraska Cancer Specialists/Oncology Hematology West PC - MEJ

Council Bluffs, Iowa, United States, 51503

Actively Recruiting

50

Mercy Medical Center - Des Moines

Des Moines, Iowa, United States, 50314

Actively Recruiting

51

Mercy Hospital South

St Louis, Missouri, United States, 63128

Actively Recruiting

52

Mercy Hospital Saint Louis

St Louis, Missouri, United States, 63141

Actively Recruiting

53

Community Hospital of Anaconda

Anaconda, Montana, United States, 59711

Actively Recruiting

54

Billings Clinic Cancer Center

Billings, Montana, United States, 59101

Actively Recruiting

55

Bozeman Health Deaconess Hospital

Bozeman, Montana, United States, 59715

Actively Recruiting

56

Benefis Sletten Cancer Institute

Great Falls, Montana, United States, 59405

Actively Recruiting

57

Logan Health Medical Center

Kalispell, Montana, United States, 59901

Actively Recruiting

58

Community Medical Center

Missoula, Montana, United States, 59804

Actively Recruiting

59

Nebraska Cancer Specialists/Oncology Hematology West PC - MECC

Omaha, Nebraska, United States, 68114

Actively Recruiting

60

Nebraska Methodist Hospital

Omaha, Nebraska, United States, 68114

Actively Recruiting

61

Oncology Associates PC

Omaha, Nebraska, United States, 68114

Suspended

62

University of Cincinnati Cancer Center-UC Medical Center

Cincinnati, Ohio, United States, 45219

Active, Not Recruiting

63

University of Cincinnati Cancer Center-West Chester

West Chester, Ohio, United States, 45069

Active, Not Recruiting

64

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, United States, 73104

Actively Recruiting

65

Oklahoma Cancer Specialists and Research Institute-Tulsa

Tulsa, Oklahoma, United States, 74146

Suspended

66

Saint Alphonsus Cancer Care Center-Ontario

Ontario, Oregon, United States, 97914

Suspended

67

Providence Portland Medical Center

Portland, Oregon, United States, 97213

Actively Recruiting

68

Providence Saint Vincent Medical Center

Portland, Oregon, United States, 97225

Actively Recruiting

69

Medical University of South Carolina

Charleston, South Carolina, United States, 29425

Actively Recruiting

70

Swedish Medical Center-First Hill

Seattle, Washington, United States, 98122

Actively Recruiting

71

ProHealth D N Greenwald Center

Mukwonago, Wisconsin, United States, 53149

Actively Recruiting

72

ProHealth Oconomowoc Memorial Hospital

Oconomowoc, Wisconsin, United States, 53066

Actively Recruiting

73

ProHealth Waukesha Memorial Hospital

Waukesha, Wisconsin, United States, 53188

Actively Recruiting

74

UW Cancer Center at ProHealth Care

Waukesha, Wisconsin, United States, 53188

Actively Recruiting

75

Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia, 3000

Actively Recruiting

76

University Health Network-Princess Margaret Hospital

Toronto, Ontario, Canada, M5G 2M9

Actively Recruiting

77

Chinese University of Hong Kong-Prince of Wales Hospital

Shatin, Hong Kong

Suspended

78

National University Hospital Singapore

Singapore, Singapore, 119074

Actively Recruiting

79

National Cancer Centre Singapore

Singapore, Singapore, 168583

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer | DecenTrialz